404
Immune Checkpoint Inhibitors Market Report
Immune Checkpoint Inhibitors Market Trends, Dynamics & Market Insights
Immune Checkpoint Inhibitors Market, By Inhibitor Type (CTLA-4 Inhibitors, PD-1 Inhibitors, Others), By Application (Hodgkin Lymphoma, Kidney Cancers, Melanoma, Non-small Cell Lung Cancer, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Region ...
The immune checkpoint inhibitors market is expected to witness an impressive growth of 18.2% CAGR in the foreseeable future.
Bristol-Myers Squibb Company (US), Merck & Co. (US), F. Hoffmann-La Roche AG (Switzer-land), Regeneron Pharmaceuticals Inc. (US), AstraZeneca PLC (UK), Eli Lilly and Company (AR-MO Biosciences.) (US), Fortress Biotech, Inc. (US), Novartis AG (Switzerland), and Pfizer Inc. (US) are among the key players in the immune checkpoint inhibitors market.
Technological developments in screening procedures for cancer, increase in government initiatives to cure cancer, growing healthcare expenditures, and rise in public awareness are the factors driving the growth of immune checkpoint inhibitors market.
The PD-1 inhibitors segment accounted for a substantial share in the immune checkpoint inhibitors market in 2020.
North America is expected to remain dominant in the immune checkpoint inhibitors market in the next five years.
Immune Checkpoint Inhibitors distributors, Immune Checkpoint Inhibitors suppliers, Immune Checkpoint Inhibitors manufacturers, Hospitals, Government bodies are the target audience in the immune checkpoint inhibitors market.